Wacker reports record sales for 2022

Munich, Germany – As already reported, Wacker Chemie AG ended 2022 with new all-time highs for sales and earnings. Presenting its annual report, the Munich-based chemical company confirmed Group sales of €8.21 billion in 2022 (2021: €6.21 billion), up 32 percent year over year. Substantially higher selling prices were the main growth driver. Sales also benefited from positive exchange-rate effects due to the stronger US dollar. On the other hand, overall volumes were down somewhat versus the previous year, dampening sales.
In 2022, Group EBITDA rose 35 percent year over year, coming in at €2.08 billion (2021: €1.54 billion), yielding an EBITDA margin of 25.4 percent (2021: 24.8 percent). In addition to a marked increase in sales, cost savings from the Group’s ongoing efficiency programs had a positive impact on operating performance. On the other hand, sharp increases in energy, raw-material and logistics costs weighed on EBITDA, amounting to additional costs of around €1.3 billion year over year.
Due to the effects described above, Group EBIT grew by 48 percent to around €1.68 billion (2021: €1.13 billion), resulting in an EBIT margin of 20.5 percent (2021: 18.3 percent). Depreciation and amortization amounted to €402 million in 2022 (2021: €404 million). Net income for 2022 was €1.28 billion (2021: €828 million).
WACKER is headed for a new record with its dividend. The Executive and Supervisory Boards will propose a dividend of €12.00 per share at the Annual Shareholders’ Meeting. Accordingly, WACKER will be distributing roughly 50 percent of its net income for the year, in line with its dividend policy. Based on the number of shares entitled to dividends as of December 31, 2022, the total cash dividend corresponds to a payout of €596 million. Calculated in relation to WACKER’s average share price in 2022, the dividend yield is 8.6 percent.
“The war in Europe is an acid test for the entire world and has thrown the global economy off balance,” said CEO Christian Hartel in Munich on Tuesday. Amid these unpredictable and unstable conditions, he said, WACKER had had a highly successful business year: “With €8.2 billion in sales and EBITDA of more than €2 billion, it was by far the most successful year in the company’s history.”
From today’s point of view, this strong operational growth, which WACKER was able to achieve in the past couple of years, will not continue in 2023. “The global economy has slowed significantly. Around the world, the economic and political environment remains volatile. High energy prices, especially in Europe, continue to impact our business,” Hartel said.
In the first two months of this year, demand declined across a large number of customer sectors, with Group sales and EBITDA both lower than last year. Overall, WACKER expects to post Group sales of about €1.7 billion in Q1 2023 (Q1 2022: €2.08 billion). Group EBITDA will also be lower in Q1 2023. It is expected to come in between €250 million and €280 million, amid lower selling prices and declining volumes.
WACKER expects to post Group sales of between €7 billion and €7.5 billion in 2023, due to a combination of significantly lower selling prices, volume growth in the course of the year and positive product-mix effects in the chemical divisions. Based on these trends, Group EBITDA is expected to come in between €1.1 billion and €1.4 billion. Slightly higher energy costs will also dampen EBITDA.
“Even though we currently face economic headwinds rather than tailwinds, we look to the future with optimism,” Hartel went on to say. Last year WACKER had plotted its strategic course for the coming years. “Our Strategy 2030 provides us with clear goals: faster growth, high profitability and better resilience in times of constant change,” Hartel explained. He stated that a key component in achieving these goals would be higher investments, which would be spread across more than 40 different projects and rise to around €650 million in 2023. “Investments at our chemical divisions will focus mainly on expanding our portfolio of specialty products. In the biotechnology field, we will ramp up the ongoing expansion of our sites. In our polysilicon business, the focus will be on semiconductor applications,” said Hartel.